# Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

> **NCT04639986** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 331 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Sacituzumab Govitecan-hziy
- **DRUG:** Eribulin Mesylate Injection
- **DRUG:** Capecitabine Oral Product
- **DRUG:** Gemcitabine Injection
- **DRUG:** Vinorelbine injection

## Key facts

- **NCT ID:** NCT04639986
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-23
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639986, "Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04639986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*